Psychiatric symptoms of noradrenergic dysfunction: A pathophysiological view

Psychiatry and Clinical Neurosciences

Volumn 68, Issue 1, 2014, Pages 1-20

  Yamamoto, Ken Ichi ^a   Shinba, Toshikazu ^a   Yoshii, Mitsunobu ^a  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

hyperarousal symptoms; locus coeruleus; noradrenaline; pathophysiology; stress

Indexed keywords

AMPHETAMINE; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CLONIDINE; COCAINE; DESIPRAMINE; EPHEDRINE; HALOPERIDOL; IMIPRAMINE; LEVODOPA; METHYLPHENIDATE; METIROSINE; NEUROLEPTIC AGENT; NIALAMIDE; PIPEROXAN; PRAZOSIN; PROPRANOLOL; RESERPINE; YOHIMBINE;

ACUTE STRESS; ADRENERGIC SYSTEM; AGGRESSIVENESS; ALERTNESS; ANXIETY; ANXIETY DISORDER; AROUSAL; AUDITORY CORTEX; AUDITORY HALLUCINATION; BRAIN CORTEX; CHRONIC STRESS; DEMENTIA; DEPRESSION; ELECTRODERMAL RESPONSE; ELECTROENCEPHALOGRAM; ELECTROENCEPHALOGRAPHY; ELECTROENCEPHALOGRAPHY PHASE SYNCHRONIZATION; ELECTROSTIMULATION; ELEVATED BLOOD PRESSURE; ELEVATED PLUS MAZE TEST; EMOTION; ESSENTIAL HYPERTENSION; EVENT RELATED POTENTIAL; EVOKED RESPONSE; EXECUTIVE FUNCTION; FEAR; FOOTSHOCK; FREQUENCY ANALYSIS; GENERALIZED ANXIETY DISORDER; HABITUATION; HEART RATE; HIPPOCAMPUS; HUMAN; HYPERSENSITIVITY; HYPERSOMNIA; IMMOBILIZATION STRESS; INSOMNIA; INSTRUMENTAL CONDITIONING; IRRITABILITY; LATENT PERIOD; MANIA; MEMBRANE DEPOLARIZATION; MENTAL DISEASE; MENTAL INSTABILITY; MOOD DISORDER; MUSCLE TONE; NEGATIVE FEEDBACK; NEGATIVE SYNDROME; NERVE CELL; NERVE ENDING; NEUROLOGIC DISEASE; NONHUMAN; NORADRENERGIC DYSFUNCTION; NORADRENERGIC SYSTEM; PANIC; PARANOID SCHIZOPHRENIA; PERSECUTORY DELUSION; POSITIVE SYNDROME; POSITRON EMISSION TOMOGRAPHY; POSTTRAUMATIC STRESS DISORDER; PSYCHOPHYSIOLOGY; REM SLEEP; RESTLESSNESS; REVIEW; SCHIZOPHRENIA; SELECTIVE ATTENTION; SENSORY NERVE; SENSORY STIMULATION; SKIN CONDUCTANCE; SLEEP DISORDER; STARTLE REFLEX; STRESS; STRIA TERMINALIS; SYMPATHETIC TONE; SYMPTOM; SYSTOLIC BLOOD PRESSURE; TENSION; VISUAL DISCRIMINATION; ADRENERGIC NERVE CELL; ANIMAL; BEHAVIOR; COMPLICATION; DRUG EFFECTS; DRUG THERAPY; MENTAL DISORDERS; MENTAL STRESS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY;

ADRENERGIC NEURONS; ANIMALS; ANTI-ANXIETY AGENTS; ANTIPSYCHOTIC AGENTS; AROUSAL; BEHAVIORAL SYMPTOMS; HUMANS; MENTAL DISORDERS; STRESS, PSYCHOLOGICAL;

EID: 84891829628     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/pcn.12126     Document Type: Review

References (211)

1. von Euler US,. A specific sympathomimetic ergone in adrenergic nerve fibers (sympathin) and its relation to adrenaline and noradrenaline. Acta Physiol. Scand. 1946; 12: 78-97.
2. Cannon WB,. Bodily Changes in Pain, Hunger, Fear and Rage. McGrath Publishing Company, College Park, 1929.
3. Selye H,. A syndrome produced by diverse noxious agents. Nature 1936; 138: 32-36.
4. Vogt M,. The concentration of sympathin in different parts of the central nervous system under normal conditions and after the administration of drugs. J. Physiol. 1954; 123: 451-481.
5. Carlson A, Falk B, Hillarp NA, Thieme G, Trop A,. A new histochemical method for visualization of tissue catecholamines. Med. Exp. Int. J. Exp. Med. 1961; 4: 123-125.
6. Bloom FE,. Commentary: Physician-scientist's frustrations fester. Neuropsychopharmacology 2009; 34: 1-5.
7. Darhström A, Fuxe K,. Evidence for the existence of monoamine-containing neurons in the central nervous system. Acta Physiol. Scand. 1964; 62 (Suppl. 232): 5-55.
8. Moore RY, Bloom FE,. Central catecholamine neuron systems: Anatomy and physiology of norepinephrine and epinephrine systems. Annu. Rev. Neurosci. 1979; 2: 113-168.
9. Westlund KN, Coulter JP,. Descending projections of the locus coeruleus and subcoeruleus/medial parabrachial nucleus in monkey: Axonal transport studies and dopamine-beta-hydroxylase immunocytochemistry. Brain Res. 1980; 2: 235-264.
10. Maeda T, Shimizu N,. The locus coeruleus. Brain Nerv. 1982; 139: 565-570 (in Japanese).
11. Foote SL, Bloom FE, Aston-Jones G,. Nucleus locus coeruleus: New evidence of anatomical and physiological specificity. Physiol. Rev. 1983; 63: 844-914.
12. Yamamoto K, Kaneko H, Ozawa N, Hoshino T,. The central noradrenergic system and vigilance. In:, Segawa M, (ed.). Brain, Midbrain, Telencephalon and Behavior. Sanposha, Tokyo, 1988; 63-69.
13. Loewy AD, Marson L, Parkinson D, Perry MA, Sawyer WB,. Descending noradrenergic pathways involved in the A5 depressor response. Brain Res. 1986; 386: 313-324.
14. Huangfu D, Hwang LJ, Riley TA, Guyenet PG,. Splanchnic nerve response to A5 area stimulation in rats. Am. J. Physiol. 1992; 263: R437-R446.
15. Cunningham FT Jr, Sawchenk PE,. Anatomical specificity of noradrenergic inputs to the paraventricular and supraoptic nuclei of the rat hypothalamus. J. Comp. Neuerol. 1988; 274: 60-76.
16. Gieroba ZJ, Blessing WW,. Vasopressin secretion after stimulation of abdominal vagus in rabbit: Role of Al norepinephrine neurons. Am. J. Physiol. 1994; 266: R1885-R1890.
17. Huangfu DH, Koshiya N, Guyenet PG,. A5 noradrenergic unit activity and sympathetic nerve discharge in rats. Am. J. Physiol. 1992; 261: R393-R402.
18. Woodruff ML, Baisden RH, Whittington DL,. Effects of electrical stimulation of the pontine A5 cell group on blood pressure and heart rate in the rabbit. Brain Res. 1983; 379: 12-23.
19. Kostrzewa RM, Jacobowitz DM,. Pharmacological actions of 6-hydroxydopamine. Pharmacol. Rev. 1974; 26: 199-288.
20. Dayas CV, Buller KM, Day TA,. Medullary neurones regulate hypothalamic cortiocotropin-releasing factor cell responses to an emotional stressor. Neurosci. 2001; 105: 707-719.
21. Saphier D,. Catecholaminergic projections to tuberoinfundibular neurons of the paraventricular nucleus: I. Effects of stimulation of A1, A2, A6 and C2 cell groups. Brain Res. Bull. 1989; 23: 389-395.
22. Dunn AJ, Swiergiel AH, Palamarchouk V,. Brain circuits involved in corticotrophin-releasing factor-norepinephrine interactions during stress. Ann. N. Y. Acad. Sci. 2004; 1018: 25-34.
23. Elam M, Svensson TH, Thoren P,. Locus coeruleus and sympathetic nerves: Activation by cutaneous sensory afferents. Brain Res. 1986; 366: 254-261.
24. Reiner PB,. Correlational analysis of central noradrenergic neuronal activity and sympathetic tone in behaving cats. Brain Res. 1986; 378: 86-96.
25. Abercrombie ED, Jacobs B,. Single unit response of noradrenergic neurons in the locus coeruleus of free moving cats. I. Acutely presented stressful and nonstressful stimuli. J. Neurosci. 1987; 7: 2837-2843.
26. Hobson JA, McCarley RW, Wysinski PW,. Sleep cycle oscillation: Reciprocal discharge by two brainstem neuronal groups. Science 1975; 189: 55-58.
27. Aston-Jones G, Bloom FE,. Activity of norepinephrine-containing locus coeruleus neurons in behaving rats anticipates fluctuations in the sleep-waking cycle. J. Neurosci. 1981; 1: 876-886.
28. Foote SL, Aston-Jones G, Bloom FE,. Impulse activity of locus coeruleus neurons in awake rats and arousal. Proc. Natl. Acad. Sci. U.S.A. 1980; 77: 3033-3037.
29. de Sarro GB, Bagetta G, Ascioti C, Frorio F, Libri V, Nistico G,. Microinfusion of clonidine and yohimbine into locus coeruleus alters EEG power spectrum: Effect of aging and reversal by phosphatidylserine. Br. J. Pharmacol. 1988; 95: 1278-1286.
30. Yamamoto K, Ozawa N,. Increased firing of locus coeruleus associated with preparatory set in rats. Neurosci. Lett. 1989; 106: 112-118.
31. Yamamoto K, Ozawa N, Shinba T, Andou T,. Noradrenergic modulation of the smooth pursuit eye movement in monkeys. Soc. Neurosci. Abstr. 1991; 16: 114.
32. Aston-Jones G, Rajkowski J, Kubiak P, Alexinsky T,. Locus coeruleus neurons in monkey are selectively activated by attended cues in a vigilance task. J. Neurosci. 1994; 14: 4467-4480.
33. Hebb DO,. A Textbook of Psychology. W.B. Saunders, New York, 1958.
34. Bunsey MD, Strupp BJ,. Specific effect of idazoxan in a distraction task: Evidence that endogenous norepinephrine plays a role in selective attention task. Behav. Neurosci. 1995; 109: 903-911.
35. Bremner JD, Krystal JK, Sowthwick SM, Charney DS,. Noradrenergic mechanisms in stress and anxiety: I. Preclinical studies. Synapse 1996; 23: 28-38.
36. Tanaka M, Yoshida M, Emoto H, Ishii H,. Noradrenaline systems in the hypothalamus, amygdala and locus coeruleus are involved in the provocation of anxiety: Basic studies. Eur. J. Pharmacol. 2000; 405: 397-406.
37. Yokoo H, Tanaka M, Yoshida M, Tsuda A, Tanaka T, Mizoguchi K,. Direct evidence of conditioned fear-elicited enhancement of noradrenaline release in the rat hypothalamus assessed by intracranial microdialysis. Brain Res. 1990; 536: 305-308.
38. Iversen S, Kupfermann I, Kandel ER,. Emotional states and feelings. In:, Kandel ER, Schwartz JH, Jessell TM, (eds). Principles of Neural Science. McGraw-Hill, New York, 2000; 982-997.
39. Holmberg G, Gershon S,. Autonomic and psychic effects of yohimbine hydrochloride. Psychopharmacol. (Berl) 1961; 2: 93-106.
40. Charney DS, Woods SW, Heninger GR,. Noradrenergic function in generalized anxiety disorder: Effects of yohimbine in healthy subjects and patients with generalized anxiety disorder. Psychiatry Res. 1989; 27: 173-185.
41. Albus M, Zahn TP, Breier A,. Anxiogenic properties of yohimbine. I. Behavioral, physiological and biochemical measures. Eur. Arch. Psychiatry Clin. Neurosci. 1992; 241: 337-344.
42. Johnston AL, File SE,. Yohimbine's anxiogenic action: Evidence for noradrenergic and dopaminergic sites. Pharmacol. Biochem. Behav. 1989; 32: 151-155.
43. Rogireo R, Takahashi RN,. Anxiogenic properties of cocaine in the rat evaluated with elevated plus maze. Pharmacol. Biochem. Behav. 1992; 43: 631-633.
44. Schank JR, Liles LC, Weinshenker D,. Norepinephrine signaling through β-adrenergic receptors is critical for expression of cocaine-induced anxiety. Biol. Psychiatry 2008; 63: 1007-1012.
45. Kokkinidis L, Anisman H,. Involvement of norepinephrine in startle arousal after acute and chronic d-amphetamine administration. Psychopharmacol. (Berl) 1978; 59: 285-292.
46. Davis M, Redmond DE Jr, Baraban JM,. Noradrenergic agonists and antagonists: Effects on conditioned fear as measured by the potentiated startle paradigm. Psychopharmacol. (Berl) 1979; 65: 111-118.
47. Davis M, Falls WA, Campeau S, Kim M,. Fear-potentiated startle: a neural and pharmacological analysis. Behav. Brain Res. 1993; 58: 175-198.
48. Neophytou SI, Aspley S, Butler S, Beckett S, Marsden CA,. Effects of lesioning noradrenergic neurons in the locus coeruleus on conditioned and unconditioned aversive behavior in the rat. Prog. Neuropsychopharmacol. Biol. Psychiatry 2001; 25: 1307-1321.
49. Davis M,. Neurobiology of fear responses: The role of amygdala. J. Neuropsychiatry Clin. Neurosci. 1997; 9: 382-402.
50. Schulz B, Fendt M, Schnitzler HU,. Clonidine injections into the lateral nucleus of the amygdala block acquisition and expression of fear-potentiated startle. Eur. J. Neurosci. 2002; 15: 151-157.
51. Schwemer J, Fendt M, Schnitzler HU,. Effects of clonidine injections into the bed nucleus of the stria terminalis on fear and anxiety behavior in rats. Eur. J. Pharmacol. 2005; 507: 117-124.
52. Nakamura K, Thoenen H,. Increased irritability: A permanent behavior change induced in the rat by intraventricular administration of 6-hydroxydopamine. Psychopharmacologia 1972; 24: 359-372.
53. Beleslin DB, Samardzic R, Krstic SK, Micic D, Terzic B,. Comparison of behavioral changes in cats treated with intracerebroventricular 6-hydroxydopamine and reserpine. Brain Res. Bull. 1981; 6: 285-287.
54. Sorenson CA, Gordon M,. Effects of 6-hydroxydopamine on shock-elicited aggression, emotionality and maternal behavior in female rats. Pharmacol. Biochem. Behav. 1975; 3: 331-335.
55. Thoa NB, Eichelman B, Ng LKY,. Shock-induced aggression: Effect of 6-hydroxydopamine and other pharmacological agents. Brain Res. 1972; 43: 467-475.
56. Thoa NB, Eichelman B, Richardson JB, et al. 6-Hydroxydopa depletion of brain norepinephrine and facilitation of aggressive behavior. Science 1972; 178: 75-77.
57. Lader MH,. The psychophysiology of anxiety. In:, van Praag HM, Lader MH, Rafaelsen UJ, Sachar EJ, (eds). Handbook of Biological Psychiatry II. Marcel Dekker, New York, 1980; 225-248.
58. Koella WP,. A modern neurobiological concept of vigilance. Experientia 1982; 38: 1426-1437.
59. Sternbach RA,. Principles of Psychophysiology. Academic Press, New York, 1966.
60. Lader MH,. Comparison of amphetamine sulphate and caffeine citrate in man. Psychopharmacol. (Berl) 1969; 14: 83-94.
61. Yamamoto K, Ozawa N, Shinba T, Hoshino T,. Functional influence of the central noradrenergic system of the skin conductance activity in rats. Schizophr. Res. 1994; 13: 145-150.
62. Yamamoto K, Arai H, Nakayama S,. Skin conductance response after 6-hydroxydopamine lesion of the central noradrenergic system in cats. Biol. Psychiatry 1990; 28: 151-160.
63. Yamamoto K, Hagino K, Moroji T, Ishii T,. Habituation failure of skin conductance response after intraventricular administration of 6-hydroxydopamine in cats. Experientia 1984; 40: 344-345.
64. Yamamoto K, Hoshino T, Takahashi Y,. Skin conductance activity after intraventricular 6-hydroxydopa in rats. Biol. Psychiatry 1991; 29: 365-375.
65. Berridge CW, Page ME, Valentino RJ, Foote SL,. Effects of locus coeruleus inactivation on electoroencephalographic activity in neocortex and hippocampus. Neuroscience 1993; 55: 381-393.
66. Berridge CW, Foote SL,. Effects of locus coeruleus activation on electroencephalographic activity in neocortex and hippocampus. J. Neurosci. 1991; 11: 3135-3145.
67. Shinba T, Ando Y, Ozawa N, Yamamoto K,. Auditory-evoked response of the cortex after yohimbine administration: Phase advance effect of central noradrenergic activation. Brain Res. Bull. 1992; 28: 463-471.
68. Turetsky BI, Fein G,. Alpha2-noradrenergic effect on ERP and behavioral indices of auditory information processing. Psychophysiol. 2002; 39: 147-157.
69. Nieuwenhuis S, Aston-Jones G, Cohen JD,. Decision making, the P3 and the locus coeruleus norepinephrine system. Psychol. Bull. 2005; 131: 510-532.
70. Pineda JA, Foote SL, Neville HJ,. Effect of locus coeruleus lesions on auditory, long-latency, event-related potentials in monkey. J. Neurosci. 1989; 9: 81-93.
71. Swick D, Pineda JA, Foote SL,. Effects of systemic clonidine on auditory event-related potentials in squirrel monkeys. Brain Res. Bull. 1994; 33: 79-86.
72. Halliday R, Naylor H, Brandeis D, Callaway E, Yano L, Herzig K,. The effect of d-amphetamine, clonidine, and yohimbine on human information processing. Psychophysiol. 1994; 31: 331-337.
73. Mervaala E, Alheinen K, Helkala E-L, et al. Electrophysiological and neurophysiological effects of a central alpha2-antagonist atipamezole in healthy volunteers. Behav. Brain Res. 1993; 55: 85-91.
74. Rajkowsky J, Kubiak P, Aston-Jones G,. Locus coeruleus activity in monkey: Phasic and tonic changes are associated with altered vigilance. Brain Res. Bull. 1994; 35: 607-616.
75. American Psychiatric Association. DSM-III: Diagnostic and Statistical Manual of Mental Disorders, 3rd edn. APA, Washington, DC, 1980.
76. American Psychiatric Association. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, 4th edn. APA, Washington, DC, 1994.
77. Pitman RK, Orr SP, Forgue DF, de Jong JB, Claiborn JM,. Psychophysiologic assessment of posttraumatic stress disorder imagery in Vietnam combat veterans. Arch. Gen. Psychiatry 1987; 44: 970-975.
78. Friedman MJ, Yehuda R,. Post-traumatic stress disorder and comorbidity. Psychobiological approaches to differential diagnosis. In:, Friedman MJ, Charney DS, Denich AY, (eds). Neurobiological and Clinical Consequences of Stress. Lippincots-Raven, Philadelhpia, PA, 1995; 429-445.
79. Shalev AY, Orr SP, Peri T, Schreiber S, Pitman RK,. Physiological responses to loud tones in Israeli patients with posttraumatic stress disorder. Arch. Gen. Psychiatry 1992; 49: 870-875.
80. Karl A, Malta LS, Maercker A,. Meta-analytic review of event-related potential studies in post-traumatic stress disorder. Biol. Psychol. 2006; 71: 123-147.
81. Geracioti TD, Baker DG, Ekhator NN, et al. CSF norepinephrine concentrations in posttraumatic stress disorder. Am. J. Psychiatry 2001; 158: 1227-1230.
82. Famularo R, Kinsiherff R, Feuton T,. Propranolol treatment for childhood posttraumatic stress disorder, acute type: A pilot study. Am. J. Dis. Child. 1988; 142: 1244-1247.
83. Kinzie JD, Leung P,. Clonidine in Cambodian patients with posttraumatic stress disorder. J. Nerv. Ment. Dis. 1989; 177: 546-550.
84. Porter DM, Bell CC,. The use of clonidine in post-traumatic stress disorder. J. Natl. Med. Assoc. 1999; 91: 475-477.
85. Boehnlein JK, Kinzie JD,. Pharmacological reduction of CNS noradrenergic activity in PTSD: The case for clonidine and prazosine. J. Psychiatr. Pract. 2007; 13: 72-78.
86. Calohan J, Peterson K, Peskind K, Raskind MA,. Prazosin treatment of trauma nightmares and sleep disturbances in soldiers deployed in Iraq. J. Trauma. Stress 2010; 23: 646-648.
87. Bracha HS, Garcia-Rill E, Mark RE, Skinner R,. Postmortem locus coeruleus neuron count in three American veterans with possible war-related PTSD. J. Neuropsychiatry Clin. Neurosci. 2005; 17: 503-509.
88. Southwick SM, Bremner JD, Rasmusson A, Morgan CA, Arnsten A, Charney DS,. Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder. Biol. Psychiatry 1999; 46: 1192-1204.
89. O'Donnell T, Haegadoren KM, Coupland NC,. Noradrenergic mechanisms in the pathophysiology of post-traumatic stress disorder. Neuropsychobiol. 2004; 50: 273-283.
90. Birket SM, Hasle N, Jensen HH,. Electrodermal activity in anxiety disorders. Acta Psychiatr. Scand. 1993; 88: 350-355.
91. Hoehn T, Braune S, Scheibe G, Albus M,. Physiological, biochemical and subjective parameters in anxiety patients with panic disorders during stress exposure as compared with healthy controls. Eur. Arch. Psychiatry Clin. Neurosci. 1997; 247: 264-274.
92. Roth WT, Wilhelm FH, Trabert W,. Autonomic instability during relaxation in panic disorder. Psychiatry Res. 1998; 80: 155-164.
93. Clark CR, McFarlane AC, Weber DL, Battersky M,. Enlarged frontal P300 to stimulus change in panic disorder. Biol. Psychiatry 1996; 39: 845-856.
94. Gordeev SA,. Cognitive functions and the state of nonspecific brain systems in panic disorders. Neurosci. Behav. Physiol. 2008; 38: 707-714.
95. Charney DS, Woods SW, Krystal JH, Nagy LM, Heninger GH,. Noradrenergic neuronal dysregulation in panic disorder: The effects of intravenous yohimbine and clonidine in panic disorder patients. Acta Psychiatr. Scand. 1992; 86: 273-282.
96. Krystal JH, McDougles CJ, Woods SW, Price LH, Heninger GH, Charney DS,. Dose-response relationship for oral idazoxan effects in healthy human subjects: Comparison with oral yohimbine. Psychopharmacol. (Berl) 1992; 108: 313-319.
97. Fuller KH, Waters WP, Binks PG, Anderson T,. Generalized anxiety and sleep architecture: A polysomnographic investigation. Sleep 1997; 20: 370-376.
98. Sevy S, Papadimitrion GN, Surmont DW, Goldman S, Mendelwicz J,. Noradrenergic function in generalized anxiety disorder, major depressive disorder and healthy subjects. Biol. Psychiatry 1989; 25: 141-152.
99. Marcy R, Quermonne MA, Raoul J, Nammathao B, Smida A,. Skin conductance reaction (SCR)-habituation test, a tool to detect anxiolytic activity. Its justification by the correlation between SCR-habituation test activities and specific binding potencies in benzodiazepines. Prog. Neuropsychopharmacol Biol. Psychiatry 1985; 9: 387-391.
100. Hoehn-Saric R, Merchant AF, Keyser ML, Smith VK,. Effects of clonidine on anxiety disorders. Arch. Gen. Psychiatry 1981; 38: 1278-1282.
101. Hayes PE, Schulz SC,. Beta-blocker in anxiety disorders. J. Affect. Disord. 1987; 13: 119-130.
102. Lader MH,. Beta-adrenoceptor antagonists in neuropsychiatry: An update. J. Clin. Psychiatry 1988; 49: 212-223.
103. Kalk NJ, Nutt J, Lingford-Hughes AR,. The role of central noradrenergic dysregulation in anxiety disorders: Evidence from clinical studies. J. Psychopharmacol. 2011; 25: 3-16.
104. Klerman GL,. Depression and related disorders of mood (affective disorders). In:, Nicholi AM, (ed.). The New Harvard of Psychiatry. Harvard University Press, Cambridge, 1988; 309-336.
105. Fava M, Rankin MA, Wright EC, et al. Anxiety disorders in major depression. Compr. Psychiatry 2000; 41: 97-102.
106. Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus depression: A STARD report. Am. J. Psychiatry 2008; 165: 342-351.
107. Lader MH, Wing L,. Physiological measures in agitated and retarded depressed patients. J. Psychiatr. Res. 1969; 7: 89-100.
108. Roy A, Pickar D, Linonola M, Doran AR, Ninan P, Paul SM,. Cerebrospinal fluid monoamine and monoamine metabolite concentrations in melancholia. Psychiatry Res. 1985; 15: 281-292.
109. Redmond DE, Katz MM, Maas JW, Swann A, Casper R, Davis JM,. Cerebrospinal fluid amine metabolites. Relationships with behavioral measurements in depressed, manic and healthy control subjects. Arch. Gen. Psychiatry 1986; 43: 938-947.
110. Jimmerson DC, Post RM, Stoddard FJ, Gillin JC, Bunney WE Jr,. Preliminary trial of noradrenergic agonist clonidine in psychiatric patients. Biol. Psychiatry 1980; 15: 45-57.
111. Charney DS, Price LH, Heniger GR,. Desipramine-yohimbine combination treatment of refractory depression. Implications for the beta-adrenergic receptor hypothesis of antidepressant action. Arch. Gen. Psychiatry 1986; 43: 1155-1161.
112. Swann AC, Secunda S, Davis JM, et al. CSF monoamine metabolites in mania. Am. J. Psychiatry 1983; 140: 396-400.
113. Post RM, Rubinow DR, Uhde TW, Roy-Byrne PP, Linolia M, Rosoff A,. Dysphoric mania. Clinical and biological correlates. Arch. Gen. Psychiatry 1989; 46: 353-358.
114. Kraepelin E,. Manic-depressive Insanity and Paranoia. E&S Livingston, Edinburgh, 1921.
115. Hardy MC, Lecrubier Y, Widlöcher D,. Efficacy of clonidine in 24 patients with acute mania. Am. J. Psychiatry 1986; 143: 1450-1453.
116. Tudorache B, Diacicov S,. The effect of clonidine in the treatment of acute mania. Rom. J. Neurol. Psychiatry 1991; 29: 209-213.
117. Crow TJ,. Molecular pathology of schizophrenia: More than one disease process? Br. Med. J. 1980; 280: 66-68.
118. Haracz JL,. The dopamine hypothesis: An overview of studies with schizophrenic patients. Schizophr. Bull. 1982; 8: 438-469.
119. Wing JK,. Clinical concepts of schizophrenia. In:, Wing JK, (ed.). Schizophrenia: Towards a New Synthesis. Academic Press, London, 1978; 1-30.
120. Schneider K,. Klinische Psychopathologie. Thieme, Stuttgart, 1950.
121. Weinberger DR, Bigelow CB, Kleinman JE, Klein ST, Rosenblatt JE, Wyatt RJ,. Cerebral ventricular enlargement in chronic schizophrenia: An association with poor response to treatment. Arch. Gen. Psychiatry 1980; 37: 11-13.
122. Kupfer DJ, Wyatt RJ, Scott J, Snyder F,. Sleep disturbance in acute schizophrenia patient. Am. J. Psychiatry 1970; 126: 1213-1223.
123. Cemerinski E, Ho BC, Flaum M, et al. Insomnia as a predictor for symptom worsening following antipsychotic withdrawal in schizophrenia. Compr. Psychiatry 2002; 43: 393-396.
124. Gruzerier JH, Venables PH,. Skin conductance orienting activity in a heterogenous sample of schizophrenics. J. Nerv. Ment. Dis. 1972; 155: 277-287.
125. Gruzerier JH, Venables PH,. Evidence of high and low level of arousal in schizophrenics. Psychophysiol. 1975; 12: 66-73.
126. Saletu B, Kuffer B, Andere P, Grunberger J, Steinberger K,. EEG-brain mapping in schizophrenics with predominantly positive and negative symptoms. Eur. Neuropsychopharmacol. 1990; 1: 27-36.
127. Spencer KM, Niznikiewicz MA, Nestor PG, Shenton ME, McCarley RW,. Left auditory cortex gamma synchronization and auditory hallucination symptoms in schizophrenia. BMC Neurosci. 2009; 10: 85.
128. Lee SH, Wynn JK, Green MF, et al. Quantitative EEG and low resolution electromagnetic topography (LORETA) imaging of patients with persistent auditory hallucination. Schizophr. Res. 2006; 83: 111-119.
129. Saletu B,. Central measure in schizophrenia. In:, van Praag H, Lader MH, Rafaelsen OJ, Sachar EJ, (eds). Handbook of Biological Psychiatry. Part II Brain Mechanisms and Abnormal Behavior-psychophysiology. Marcel Dekker, New York, 1980; 97-144.
130. Schwarzkopf SB, Lamberti JS, Jiminetz M, Kane CF, Henricks M, Nasrallah HA,. Visual evoked potential correlates of positive/negative symptoms in schizophrenia. Biol. Psychiatry 1990; 27: 400-410.
131. Ford JM, Matholan DH, Marsh L, et al. P300 amplitude is related to clinical state in severely and moderately ill patients with schizophrenia. Biol. Psychiatry 1998; 46: 94-101.
132. Strik WK, Fallgatter AJ, Stoeber G, Franzek E, Beckman H,. Specific P300 features in patients with cycloid psychosis. Acta Psychiatr. Scand. 1996; 94: 471-476.
133. Yamamoto K, Ozawa N, Shinba T, Hoshino T, Yoshii M,. Possible noradrenergic dysfunction in schizophrenia. Brain Res. Bull. 1994; 35: 529-543.
134. Carlsson A, Lindqvist M,. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol. Toxicol. (Copenh) 1963; 20: 140-144.
135. Freedman R, Kirch D, Bell J, Adler LE, Pecevich E, Denver P,. Clonidine treatment of schizophrenia: Double-blind comparison to placebo and neuroleptic drugs. Acta Psychiatr. Scand. 1982; 65: 35-45.
136. van Kammen DP, Peters JL, van Kammen WB, et al. Clonidine treatment of schizophrenia. Can we predict treatment response? Psychiatry Res. 1989; 27: 279-311.
137. Yorkston NJ, Zaki SA, Weller MP,. DL-propranolol and chlorpromazine following admission for schizophrenia. A controlled comparison. Acta Psychiatr. Scand. 1981; 63: 13-27.
138. Hollister LE, Overall JE, Katz G, Higginbotham WE, Kimbell I,. Oxypertine and thiothixene in newly admitted schizophrenics. A further search for specific indication of antipsychotic drugs. Clin. Pharmacol. Ther. 1963; 12: 531-538.
139. Levinson DF,. Pharmacologic treatment of schizophrenia. Clin. Ther. 1991; 13: 326-352.
140. Carlson A, Persson T, Ross BE, Walinder J,. Potentiation of phenothiazines by alpha-methyl-para-tyrosine in treatment of schizophrenia. J. Neural Transm. 1972; 33: 83-90.
141. Bagdy G, Perenyi A, Frecska E, et al. Effect of adjuvant reserpine treatment on catecholamine metabolism in schizophrenic patients under long-term neuroleptic treatment. J. Neural Transm. 1980; 71: 73-78.
142. Roxanas MG, Spalding J,. Ephedrine abuse psychosis. Med. J. Aust. 1977; 2: 639-640.
143. Siris SG, Bermanzohn PC, Gonzaleg A, Mason SE, White CV, Shuwall MA,. The use of antidepressants for negative symptoms in a subset of schizophrenic patients. Psychopharmacol. Bull. 1991; 27: 331-335.
144. Kramer MS, Vogel WH, DiJohnson C, et al. Antidepressants in 'depressed' schizophrenic inpatients. A controlled trial. Arch. Gen. Psychiatry 1989; 46: 922-928.
145. Angrist B, Rotrosen J, Gershorn S,. Differential effects of amphetamine and neuroleptics on negative and positive symptoms in schizophrenia. Psychopharmacol. (Berl) 1980; 72: 17-19.
146. van Kammen DP, Boronow JJ,. Dextro-amphetamine diminishes negative symptoms in schizophrenia. Int. Clin. Psychopharmacol. 1988; 3: 111-121.
147. Janowsky DS, El-Yousef MK, Davis JM, Sekerke HJ,. Provocation of schizophrenic symptoms by intravenous administration of methylphenidate. Arch. Gen. Psychiatry 1973; 28: 185-191.
148. Brady K, Lydiard RB, Malcolm R,. Cocaine-induced psychosis. J. Clin. Psychiatry 1991; 52: 509-512.
149. Inanaga K, Nakamura Y, Inoue K,. Double-blind controlled study of l-Dopa therapy in schizophrenia. Folia Psychiatr. Neurol. Jpn 1975; 29: 123-143.
150. Brenner R, Shopsin B,. The use of monoamine oxidase inhibitors in schizophrenia. Biol. Psychiatry 1980; 15: 633-647.
151. Taminga CA, Schaffer MH, Smith RC, Davis JM,. Schizophrenic symptoms improve with apomorphine. Science 1978; 200: 567-568.
152. 2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacol. (Berl) 1992; 106: 433-438.
153. Freed WJ,. The therapeutic latency of neuroleptic drugs and nonspecific postjunctional supersensitivity. Schizophr. Bull. 1988; 14: 269-277.
154. Asberg M, Montgomery SA, Perris C, Schalling P, Sedvall G,. Comprehensive psychopathological rating scale. Acta Psychiatr. Scand. Suppl. 1978; 271: 5-27.
155. Sedvall G,. Relationships among biochemical, clinical and pharmacokinetic variables in neuroleptic-treated schizophrenic patients. Adv. Biochem. Psychopharmacol. 1980; 24: 521-528.
156. Sternberg DE, van Kammen DP, Lake CR, Ballenger JR, Marder SR, Bunne E,. The effect of pimozide on CSF norepinephrine in schizophrenia. Am. J. Psychiatry 1981; 138: 1945-1051.
157. Dinan TG, Aston-Jones G,. Chronic haloperidol inactivates brain noradrenergic neurons. Brain Res. 1985; 325: 385-388.
158. Lake CR, Sternberg DE, van Kammen DP, et al. Schizophrenia: Elevated cerebrospinal fluid norepinephrine. Science 1980; 207: 331-333.
159. Kemali D, Maj M, Iorio G, et al. Relationship between CSF noradrenaline levels, C-EEG indicators of activation and psychosis ratings in drug-free schizophrenic patients. Acta Psychiatr. Scand. 1985; 71: 19-24.
160. van Kammen DP, Peters J, van Kammen WB, et al. CSF norepinephrine in schizophrenia is elevated to relapse after haloperidol withdrawal. Biol. Psychiatry 1989; 27: 176-188.
161. Kemali D, Maj M, Galderisi S, Ariano MG, Starance F,. Factors associated with increased noradrenaline levels in schizophrenic patients. Prog. Neuropsychopharmacol Biol. Psychiatry 1990; 14: 49-59.
162. Post RM, Fink ED, Carpenter WT Jr, Goodwin FK,. Cerebrospinal fluid amine metabolites in acute schizophrenia. Arch. Gen. Psychiatry 1975; 32: 1063-1068.
163. Nyback H, Berggren BM, Hindmarsh T, Sedvall G, Wiesel FA,. Cerebroventricular size and cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy volunteers. Psychiatry Res. 1983; 9: 301-308.
164. Sternberg DE, van Kammen DP, Lerner P, et al. CSF dopamine β-hydroxylase in schizophrenia. Arch. Gen. Psychiatry 1983; 40: 743-747.
165. van Kammen DP, Mann LS, Sternberg DE, et al. Dopamine-beta-hydroxylase activity and homovanillic acid in schizophrenics with brain atrophy. Science 1983; 220: 974-977.
166. Farley I, Price KS, McCullough E, Deck JHN, Hordynski W, Hornykiewicz O,. Norepinephrine in chronic paranoid schizophrenia: Above-normal levels in limbic forebrain. Science 1978; 200: 456-458.
167. Hornykiewicz O,. Brain catecholamines in schizophrenia-a good case for noradrenaline. Nature 1982; 299: 484-486.
168. Gay N, Cottraud JA, Denoroy L, Tommasi M, Kopp N,. Possible increase of dopamine-beta-hydroxylase activity in the locus coeruleus of paranoid schizophrenic patients: A preliminary post-mortem study. Psychiatry Res. 1989; 27: 31-38.
169. Wise RJ, Stein L,. Dopamine beta-hydroxylase deficits in the brains of schizophrenic patients. Science 1973; 181: 344-347.
170. Marner L, Soborg C, Pakkenberg B,. Increased volume of the pigmented neurons in the locus coeruleus of schizophrenic subjects: A stereological study. J. Psychiatr. Res. 2005; 39: 337-345.
171. Yamamoto K, Hornykiewicz O,. Proposal for a noradrenaline hypothesis of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004; 28: 913-922.
172. Yamamoto K, Ozawa K, Shinb T, Andou T, Hoshino T,. Reproduction of psychophysiological signs in animals: Implications for a noradrenaline hypothesis of schizophrenia. In:, Moroji T, Yamamoto K, (eds). The Biology of Schizophrenia. Elsevier, Amsterdam, 1994b; 135-156.
173. Kay SR, Fiszbein A, Opler LA,. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987; 13: 261-276.
174. Owens DGC, Johnstone EC,. The disabilities of chronic schizophrenia: their nature and the factors contributing to their development. Br. J. Psychiatry 1980; 136: 384-395.
175. Bleuler E,. Dementia Praecox oder Gruppe der Schizophrenien. Leipzig, Franz Deuticke, 1911. Trans by Zinkin J. Dementia Praecox or the Group of Schizophrenias. International University Press, New York, 1958.
176. Esler M, Eikelis N, Schlaich M, et al. Human sympathetic nerve biology: Parallel influences of stress and epigenetics in essential hypertension and panic disorder. Ann. N. Y. Acad. Sci. 2008; 1148: 338-348.
177. Ferrier C, Jennings GL, Eisenhofer G, et al. Evidence for increased noradrenaline release from subcortical brain regions in essential hypertension. J. Hypertens. 1993; 11: 1217-1227.
178. Shinba T, Ozawa N, Yoshii M, Yamamoto K,. Delayed increase of brain noradrenaline after acute footshock stress in rats. Neurochem. Res. 2010; 35: 412-417.
179. Yamamoto K, Ozawa N, Nagaike-Masuda A,. A resistance to sleep after foot-shock stress in rats. Soc. Neurosci. Abstr. 2000; 26: 1758.
180. Herrman N, Lanctot K, Kahn LN,. The role of norepinephrine in behavioral and psychological symptoms of dementia. J. Neuropsychiatry Clin. Neurosci. 2004; 16: 261-276.
181. Glavin GB, Tanaka M, Tsuda A, Kohno Y, Hoaki T, Nagasaki N,. Regional rat brain noradrenaline turnover in response to restraint stress. Pharmacol. Biochem. Behav. 1983; 19: 287-290.
182. Anisman H, Zacharko RH,. Behavioral and neurochemical consequences associated with stressors. Ann. N. Y. Acad. Sci. 1987; 467: 2837-2845.
183. Irwin J, Ahluwalia P, Anisman H,. Sensitization of norepinephrine activity following acute and chronic footshock. Brain Res. 1986; 379: 98-103.
184. Hellriegel ET, D'Mello AP,. The effect of acute, chronic and chronic intermittent stress on the central noradrenergic system. Pharmacol. Biochem. Behav. 1997; 57: 207-214.
185. Salzman PM, Roth RH,. Post stimulation catecholamine synthesis and tyrosine hydroxylase activation in central noradrenergic neurons: In vivo stimulation of the locus coeruleus. J. Pharmacol. Exp. Ther. 1980; 212: 64-73.
186. Graham-Jones S, Fillenz M, Gray JA,. The effect of footshock and handling on tyrosine hydroxylase activity in synaptosomes and solubilised preparations from rat brain. Neuroscience 1982; 9: 679-686.
187. Kramarcy NR, Delanoy RD, Dunn AJ,. Footshock treatment activates catecholamine synthesis in mouse brain regions. Brain Res. 1984; 290: 311-319.
188. Liaw JJ, He JR, Baraclough CA,. Temporal changes in tyrosine hydroxylase mRNA levels in A1, A2 and locus ceruleus neurons following electrical stimulation of A1 noradrenergic neurons. Brain Res. Mol. Brain Res. 1992; 13: 171-174.
189. Kilborne EJ, Sabban EL,. Differential effect of membrane depolarization on level of tyrosine hydroxylase and dopamine beta-hydroxylase mRNAs in PC12 pheochromocytoma cells. Brain Res. Mol. Brain Res. 1990; 8: 121-127.
190. Serova LI, Nankova BB, Feng Z, Hong JS, Hutt M, Sabban EL,. Heightened
191. Rusnak M, Kretnensky R, Jerokova J, Palkovits M,. Effect of novel stressors on gene expression of tyrosine hydroxylase and monoamine transporters in brainstem noradrenergic neurons of long-term repeatedly immobilized rats. Brain Res. 2001; 899: 20-35.
192. Hatotani N, Nomura J, Kitayama I,. Changes of brain monoamines in the animal model for depression. Adv. Biosci. 1982; 40: 65-72.
193. Kitayama I,. Neuroendocrine studies on the pathogenesis of depression-changes of brain monoamines in animal model. Seishin Shinkeigaku Zasshi 1983; 85: 133-155 (in Japanese).
194. Komori T, Nomura J, Inoue K, Kitayama I,. Tyrosine hydroxylase activity in discrete brain regions of depression model rats. Jpn J. Psychiatry Neurol. 1990; 44: 747-754.
195. Kitayama I, Nakamura S, Yagu T, et al. Degeneration of locus coeruleus axons in stress induced depression model. Brain Res. Bull. 1994; 35: 573-580.
196. Olson VG, Rockett HR, Reh RK, et al. The role of norepinephrine in differential response to stress in an animal model of posttraumatic stress disorder. Biol. Psychiatry 2011; 70: 441-448.
197. Perry BD, Southwick SM, Yehuda R, Giller EL,. Adrenergic receptor regulation in posttraumatic stress disorder. In:, Giller EL, (ed.). Biological Assessment and Treatment of Posttraumatic Stress Disorder. American Psychiatric Press, Washington, DC, 1990; 87-114.
198. Abercrombi ED, Jacobs BL,. Systemic naloxone administration potentiates locus coeruleus noradrenergic neuronal activity under stressful but not non-stressful conditions. Brain Res. 1988; 441: 362-366.
199. Madison R, Davis JN,. Sprouting of noradrenergic fibers in hippocampus after medial septal lesions: Contributions of the central and peripheral nervous systems. Exp. Neurol. 1983; 80: 167-177.
200. Yamamoto K, Shinba T,. The central noradrenergic system in psychiatry. Seishin Shinkeigaku Zasshi 2009; 111: 741-761 (in Japanese).
201. Kraepelin E,. Psychiatrie. Ein Lehrbuch für Studirende und Aerzte. Lēipzig, Verlag von Johamn Ambrosivs Barth, 1899. Trans by Metoui H, Aed S. Psychiatry: A Textbook for Students and Physicians. Watson Publishing International, Canton, 1990.
202. Craddock N, Owen MJ,. The beginning of the end for the Kraepelinian dichotomy. Br. J. Psychiatry 2005; 186: 364-366.
203. Tamminga CA, Davis JM,. The neuropharmacology of psychosis. Schizophr. Bull. 2007; 33: 937-946.
204. Griesinger W,. Die Pathologie und Therapie der Psychishen Krankheiten. 2. Krabbe, Stuttgart, 1867. Trans by Robertson CL, Rutherford J. Mental Pathology and Therapeutics. Hafner, New York, 1965.
205. Kayama Y, Ohta M, Jodo E,. Firing of 'possibly' cholinergic neurons in the rat laterodorsal tegmental nucleus during sleep and wakefulness. Brain Res. 1992; 569: 210-220.
206. Yamamoto K, Mamelak AN, Quattorochi JJ, Hobson JA,. A cholinoceptive desynchronized sleep induction zone in the anterodorsal pontine tegmentum: spontaneous and drug-induced neuronal activity. Neuroscience 1990; 39: 279-304.
207. Lin JS, Sakai K, Jouvet M,. Hypothalamo-preoptic histaminergic projections in sleep-wake control in the cat. Eur. J. Neurosci. 1994; 6: 618-625.
208. Tsuda A, Tanaka M,. Differential changes in noradrenaline turnover in specific regions of rat brain produced by controllable and uncontrollable shocks. Behav. Neurosci. 1985; 99: 802-817.
209. McQuade R, Stanford SC,. A microdialysis study of the noradrenergic response in rat frontal cortex and hypothalamus to a conditioned cue for aversive, naturalistic environmental stimuli. Psychopharmacol. (Berl) 2000; 148: 201-208.
210. Svensson TH,. Peripheral, autonomic regulation of locus coeruleus noradrenergic neurons in brain: Putative implications for psychiatry and psychopharmacology. Psychopharmacology (Berl) 1987; 92: 1-7.
211. Shinba T, Kariya N, Matsui Y, Ozawa N, Matsuda Y, Yamamoto K,. Decrease in heart rate variability response to task is related to anxiety and depressiveness in normal subjects. Psychiatry Clin. Neurosci. 2008; 62: 603-609.